Pharvaris N.V. Ordinary Shares (PHVS) Dividend History

Company News

• Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

  Pharvaris, a biopharmaceutical company, has priced a public offering of 8,250,000 ordinary shares at $20.00 per share and pre-funded warrants to purchase 500,000 shares, expecting to raise approximately $175 million.

  GlobeNewswire Inc.

  Featured Companies: MS
• Ionis' (IONS) Donidalorsen Meets Late-Stage HAE Study Goal

  Ionis (IONS) reports positive phase III study results, which show that treatment with donidalorsen achieved a statistically significant reduction in HAE attacks.

  Zacks Investment Research

  Featured Companies: BCRX CTMX IONS
• Analyst Expectations for Pharvaris's Future

  Within the last quarter, Pharvaris (NASDAQ:PHVS) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 4 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 1 0 0 0 2M Ago 0 1 0 0 0 3M Ago 0 1 0 0 0 In the last 3 months, 4 analysts have offered 12-month price targets for Pharvaris. The company has an average price target of $29.5 with a high of $35.00 and a low of $24.00. Below is a summary of how these 4 analysts rated Pharvaris over the past 3 months. ...Full story available on Benzinga.com

  Benzinga
• Why Shares of Pharvaris N.V. Are Up Tuesday

  Promising news from the Food and Drug Administration spurred the healthcare stock's rise.

  The Motley Fool
• S&P 500 snaps 5-day losing streak, Dow ends 180 points higher as labor market appears to weaken

  U.S. stocks end higher on Thursday, after jobless-benefit claims rose to the highest level since February, suggesting economic growth may be slowing ahead of next week's Federal Reserve policy meeting.

  MarketWatch

  Featured Companies: BIVI CIEN COMP DJIA GME XOM